Literature DB >> 33791133

Long-Term Medical Follow-Up (for More than 15 Years) of a Patient with Stage IA Mycosis Fungoides Originally Presenting in Childhood: Remission for >15 Years with Localised Electron Beam Therapy.

Eric Bessell1, Martin Dalton2, John David Parry2.   

Abstract

A man now aged 80 years has received specialist care for stage 1A mycosis fungoides for 58 years. The disease developed in childhood. Long-term follow-up (>30 years) of patients with mycosis fungoides is infrequently described in the world literature. The disease in this patient was limited to 5 areas, but these were large (up to 25 cm in diameter). The rest of the skin was normal clinically. All 5 areas were treated separately with electron beam therapy (3-4 MeV) to a dose of 30 Gy in 15 fractions over 3 weeks between 2000 and 2005. Complete regression was obtained in all 5 areas, and the patient has been in complete remission for 15 years after living with the disease previously for over 40 years.
Copyright © 2021 Eric Bessell et al.

Entities:  

Year:  2021        PMID: 33791133      PMCID: PMC7984908          DOI: 10.1155/2021/5541246

Source DB:  PubMed          Journal:  Case Rep Dermatol Med        ISSN: 2090-6463


  8 in total

1.  British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018.

Authors:  D Gilson; S J Whittaker; F J Child; J J Scarisbrick; T M Illidge; E J Parry; M F Mohd Mustapa; L S Exton; E Kanfer; K Rezvani; C E Dearden; S L Morris
Journal:  Br J Dermatol       Date:  2018-12-17       Impact factor: 9.302

Review 2.  European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017.

Authors:  Franz Trautinger; Johanna Eder; Chalid Assaf; Martine Bagot; Antonio Cozzio; Reinhard Dummer; Robert Gniadecki; Claus-Detlev Klemke; Pablo L Ortiz-Romero; Evangelia Papadavid; Nicola Pimpinelli; Pietro Quaglino; Annamari Ranki; Julia Scarisbrick; Rudolf Stadler; Liisa Väkevä; Maarten H Vermeer; Sean Whittaker; Rein Willemze; Robert Knobler
Journal:  Eur J Cancer       Date:  2017-03-31       Impact factor: 9.162

3.  Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas.

Authors:  Pietro Quaglino; Nicola Pimpinelli; Emilio Berti; Piergiacomo Calzavara-Pinton; Giuseppe Alfonso Lombardo; Serena Rupoli; Mauro Alaibac; Ugo Bottoni; Angelo Carbone; Paolo Fava; Michele Fimiani; Angela Maria Mamusa; Stefano Titli; Pier Luigi Zinzani; Maria Grazia Bernengo
Journal:  Cancer       Date:  2012-06-06       Impact factor: 6.860

4.  Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases.

Authors:  Porcia T Bradford; Susan S Devesa; William F Anderson; Jorge R Toro
Journal:  Blood       Date:  2009-03-11       Impact factor: 22.113

5.  Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.

Authors:  Youn H Kim; Howard L Liu; Serena Mraz-Gernhard; Anna Varghese; Richard T Hoppe
Journal:  Arch Dermatol       Date:  2003-07

6.  Parapsoriasis in two children: a clinical, immunophenotypic, and immunogenotypic study.

Authors:  S Menni; R Piccinno; L Crosti; E Berti
Journal:  Pediatr Dermatol       Date:  1994-06       Impact factor: 1.588

7.  Quality of life and psychological distress in patients with cutaneous lymphoma.

Authors:  F Sampogna; M Frontani; G Baliva; G A Lombardo; G Alvetreti; C Di Pietro; S Tabolli; G Russo; D Abeni
Journal:  Br J Dermatol       Date:  2008-12-16       Impact factor: 9.302

8.  Childhood mycosis fungoides: experience of 28 patients and response to phototherapy.

Authors:  Philip M Laws; Neil H Shear; Elena Pope
Journal:  Pediatr Dermatol       Date:  2014-06-11       Impact factor: 1.588

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.